Clinical outcomes of patients hospitalized for COVID-19 and evidence-based on the pharmacological management reduce mortality in a region of the Colombian Caribbean.
COVID-19 drug treatment
Colchicine
Emerging infectious disease
Mortality determinant
Public health surveillance
Therapeutics
Journal
Journal of infection and public health
ISSN: 1876-035X
Titre abrégé: J Infect Public Health
Pays: England
ID NLM: 101487384
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
25
12
2020
revised:
20
02
2021
accepted:
28
02
2021
pubmed:
22
5
2021
medline:
9
6
2021
entrez:
21
5
2021
Statut:
ppublish
Résumé
Despite the high volume of infections, some clinical aspects of this disease are still unknown. There are currently no studies in Colombia that describe the disease's clinical and treatment aspects in detail. Describe the characteristics and clinical management of a group of admitted patients with SARS-CoV-2 infection in a private clinic in Montería, Córdoba-Colombia. A descriptive observational study was carried out between May and August 2020 in 209 hospitalized patients with a confirmed diagnosis of COVID-19. Upon admittance, clinical, sociodemographic characteristics, comorbidities, and complications were analyzed. Additionally, the effect of the following medications was described: 1-antibiotics (cefepime, piperacillin, tazobactam, meropenem, vancomycin) + low molecular weight heparin (LMWH) + corticosteroids (dexamethasone-methylprednisolone) + colchicine. 2- Antibiotic + LMWH + corticosteroids. 3-LMWH + corticosteroids. 4-LMWH + corticosteroids + colchicine. 5-Other treatments (Tocilizumab). 107 (51%) of the 209 patients with a confirmed diagnosis of COVID-19 passed away. The main comorbidities related to mortality of these hospitalized patients with COVID-19 were obesity and kidney disease (P < 0.05). The main complications associated with fatal outcomes in this group of patients were Acute Respiratory Distress Syndrome (ARDS) and sepsis (P < 0.05). Furthermore, it was evidenced that the colchicine combination showed a significant difference in reducing mortality in hospitalized patients compared to the other therapeutic regimens (P < 0.05). A mortality rate of 51% was found attributable to several factors such as advanced age, obesity, kidney disease, and an average time in days of late consultation. The implementation of the colchicine combination could reduce the mortality rate in this disease.
Identifiants
pubmed: 34020208
pii: S1876-0341(21)00057-5
doi: 10.1016/j.jiph.2021.02.013
pmc: PMC8101281
pii:
doi:
Substances chimiques
Heparin, Low-Molecular-Weight
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
696-701Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Références
Crit Care Resusc. 2020 Sep;22(3):200-211
pubmed: 32900326
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Lancet Infect Dis. 2021 May;21(5):e114
pubmed: 33031753
R Soc Open Sci. 2020 Oct 14;7(10):201199
pubmed: 33204475
Nephrol Dial Transplant. 2020 Dec 4;35(12):2083-2095
pubmed: 33275763
Nephrology (Carlton). 2021 Mar;26(3):248-251
pubmed: 33184959
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):655-659
pubmed: 32438328
J Thromb Haemost. 2020 May;18(5):1094-1099
pubmed: 32220112
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
J Thromb Thrombolysis. 2020 Aug;50(2):298-301
pubmed: 32476080
J Infect. 2020 Sep;81(3):e29-e30
pubmed: 32628960
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Circulation. 2020 Jul 7;142(1):4-6
pubmed: 32320270
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Thromb Haemost. 2020 Jun;18(6):1421-1424
pubmed: 32271988
BMC Infect Dis. 2020 Oct 22;20(1):787
pubmed: 33092539
J Thromb Haemost. 2020 Jul;18(7):1747-1751
pubmed: 32302448
J Infect. 2020 Aug;81(2):266-275
pubmed: 32473235
N Engl J Med. 2020 Jun 11;382(24):2372-2374
pubmed: 32302078
World J Urol. 2021 Aug;39(8):2987-2993
pubmed: 33481113
J Intern Med. 2021 Jul;290(1):166-178
pubmed: 33452733
Lancet. 2020 Mar 21;395(10228):e52
pubmed: 32171074
Crit Care. 2020 Aug 21;24(1):516
pubmed: 32825837
Lancet Oncol. 2020 Jul;21(7):904-913
pubmed: 32479787
JAMA Netw Open. 2020 Jun 1;3(6):e2013136
pubmed: 32579195
J Thromb Haemost. 2020 Aug;18(8):1995-2002
pubmed: 32369666
Mayo Clin Proc Innov Qual Outcomes. 2021 Feb;5(1):1-10
pubmed: 33173851
Nat Hum Behav. 2020 Aug;4(8):856-865
pubmed: 32737472
Mayo Clin Proc. 2020 Sep;95(9):2040-2042
pubmed: 32861346
BMJ Open. 2020 Nov 10;10(11):e042398
pubmed: 33172949
Epidemiol Infect. 2020 Jun 25;148:e125
pubmed: 32580792
Rev Invest Clin. 2020;72(3):165-177
pubmed: 32584326
Clin Infect Dis. 2020 Dec 3;71(9):2459-2468
pubmed: 32358954
Thromb Res. 2020 Jul;191:145-147
pubmed: 32291094
J Thromb Haemost. 2020 Jul;18(7):1738-1742
pubmed: 32302438
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143